BioPharmSignal logoBioPharmSignal

Biotech News

GoodRx Reports Second Quarter 2026 Results

GoodRx (GDRX)GoodRxEarnings

Pharma Direct and Subscription Revenue Increased 76% and 39%, Respectively, Year-Over-Year Company Raises Full-Year 2026 Revenue and Adjusted EBITDA Expectations SANTA MONICA, Calif. --(BUSINESS WIRE)--Aug. 5, 2026-- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the

Related news

GDRXGoodRx2026-07-09 20:05 EST

GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call

GDRXGoodRx2026-05-06 20:05 EST

GoodRx Reports First Quarter 2026 Results

View all latest news

GoodRx

Medication-Savings Platform GoodRx is a U.S. digital platform that helps consumers compare prescription prices and access discounts at pharmacies. Consumer and Provider Network The service connects consumers, pharmacies, pharmacy-benefit managers, manufacturers and healthcare professionals. Users access savings through the website,...

Recent company news

GDRXGoodRx2026-08-05 20:05 EST

GoodRx Reports Second Quarter 2026 Results

GDRXGoodRx2026-07-09 20:05 EST

GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call

GDRXGoodRx2026-05-27 13:00 EST

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

GDRXGoodRx2026-05-06 20:05 EST

GoodRx Reports First Quarter 2026 Results

GDRXGoodRx2026-05-01 12:10 EST

GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients

Stock data

Close
3.72 USD
Market cap
999.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States